Andere talen BioNTech SE BOERSE MUENCHEN

Aandelen

22UA

US09075V1026

Real Time BOERSE MUENCHEN Andere beurzen 13:00:32 14-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
88,55 ^EUR	-0,95%		-4,64%	-6,03%

11/06	Europese aandelen verhandeld in VS als American Depositary Receipts trend scherp lager in dinsdaghandel	MT
10/06	Europese aandelen verhandeld in de VS als American Depositary Receipts lager in de maandaghandel	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading	11/06
European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading	10/06
Indonesia ramps up fight against tuberculosis amid concerns on economic impact	10/06
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	05/06
COVID shots for JN.1 variant neutralize newer strains, vaccine makers say	05/06
BioNTech : ASCO 2024	03/06
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading	03/06
GNW-Adhoc: Phase-2-Daten für Prüfpräparat Acasunlimab (DuoBody® -PD-L1x4-1BB) in Kombination mit Pembrolizumab: Signifikante klinische Aktivität bei vorbehandeltem, metastasiertem nicht-kleinzelligem Lungenkarzinom	01/06
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)	01/06
Genmab A/S and Biontech SE Announce Initial Data from the Phase 2 Gct1046-04 Trial (NCT05117242) Evaluating Acasunlimab	01/06
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)	01/06
Phase-2-Daten für Prüfpräparat Acasunlimab (DuoBody® -PD-L1x4-1BB) in Kombination mit Pembrolizumab: Signifikante klinische Aktivität bei vorbehandeltem, metastasiertem nicht-kleinzelligem Lungenkarzinom	01/06
European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower	31/05
Patents, Policies And Privacy: The Highs And Lows Of Technology In IP	31/05
Dyadic International Inc. (DYAI): Bird Flu Vaccine Development Amid Rising Pandemic Concerns	30/05
BioNTech : Publication of the resolutions and system for the remuneration of Supervisory Board Members (resolution of the AGM on 17 May 2024)	30/05
BioNTech : Publication of the resolutions and system for the remuneration of Supervisory Board Members (resolution of the AGM on 1 June 2022)	30/05
BioNTech : Publication of the resolutions and system for the remuneration of Supervisory Board Members (resolution of the AGM on 22 June 2021)	30/05
BioNTech : Publication of the resolutions and system for the remuneration of the members of the management Board (resolution of the AGM on 17 May 2024)	30/05
BioNTech, CEPI Expand Partnership for mRNA Vaccine Ecosystem in Africa	29/05

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Headlines

BioNTech SE: waardering de kelder in

21 maart 2024 om 22:06 uur

BIONTECH : Een misser is een misser

21 maart 2024 om 14:27 uur